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Psychotic experiences are not uncommon in general popu-
lation samples, but no studies have examined to what extent 
confirmed risk variants for schizophrenia are associated 
with such experiences. A total of 3483 children in a birth 
cohort study participated in semistructured interviews for 
psychotic experiences at ages 12 and 18. We examined 
whether (1) a composite measure of risk for schizophrenia 
conferred by common alleles (polygenic score) was associ-
ated with psychotic experiences, (2) variants with genome-
wide evidence for association with schizophrenia were 
associated with psychotic experiences, and (3) we could 
identify genetic variants for psychotic experiences using a 
genome-wide association (GWA) approach. We found no 
evidence that a schizophrenia polygenic score, or variants 
showing genome-wide evidence of association with schizo-
phrenia, were associated with adolescent psychotic expe-
riences within the general population. In fact, individuals 
who had a higher number of risk alleles for genome-wide 
hits for schizophrenia showed a decreased risk of psychotic 
experiences. In the GWA study, no variants showed GWA 
for psychotic experiences, and there was no evidence that 
the strongest hits (P < 5 × 10−5) were enriched for variants 
associated with schizophrenia in large consortia. Although 
polygenic scores are weak tools for prediction of schizo-
phrenia, they show strong evidence of association with 
this disorder. Our findings, however, lend little support to 
the hypothesis that psychotic experiences in population-
based samples of adolescents share a comparable genetic 
architecture to schizophrenia, or that utilizing a broader 
and more common phenotype of psychotic experiences will 
be an efficient approach to increase understanding of the 
genetic etiology of schizophrenia.
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Introduction
The public health burden caused by schizophrenia and 
other psychotic disorders is a strong driver for research 
aimed at understanding the biological mechanisms under-
lying etiology that might potentially impact upon devel-
opment of novel treatments. Although schizophrenia is 
an uncommon illness characterized by a relatively diverse 
phenotype, psychotic experiences are a key feature of this 
disorder and are reported by approximately 5%–10% of the 
general population.1 Such experiences are associated with 
an increased risk of developing psychotic disorders later in 
life.2–7 This has driven a body of research using psychotic 
experiences as a more common and potentially more pow-
erful alternative phenotype to the clinical disorder itself, 
the premise being that psychotic experiences offer a strong 
indicator of underlying risk, which is only sometimes fully 
expressed as a clinical disorder. However, the positive pre-
dictive value of psychotic experiences in these studies is 
low, and therefore it is not clear to what extent studying 
this phenotype will aid understanding of the pathogenesis 
of schizophrenia, including its genetic etiology.
Recent findings from genome-wide association studies 
(GWAS) and genome-wide studies of copy number varia-
tion provide strong evidence, implicating a number of 
genetic loci as risk factors for schizophrenia.8 There is also 
increasing evidence of shared genetic contribution across 
different psychotic disorders, with most research based 
on GWAS data focusing on the overlap between schizo-
phrenia and bipolar disorder.8–10 For example, a composite 
measure of risk conferred by common alleles (known as 
a polygenic score) derived from a discovery schizophrenia 
sample has been shown to successfully discriminate indi-
viduals with schizophrenia, and with bipolar disorder, in 
other samples.11
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Twin studies provide some support that psychotic expe-
riences are also heritable,12,13 but there has been a lack of 
studies examining the impact of specific genetic loci on 
psychotic experiences,14 and no studies have examined to 
what extent confirmed risk variants for schizophrenia are 
associated with such experiences in a general population 
sample. The extent to which the genetic architecture of 
psychotic experiences in the general population is com-
parable to that of schizophrenia is, therefore, unknown.
Our primary aim in this study was to examine whether 
a composite measure of risk for schizophrenia, conferred 
by common alleles and derived using the largest published 
GWAS of this disorder, shows association with psychotic 
experiences. As secondary aims we also examine:
•	 Whether	 specific	 variants	 within	 a	 number	 of	 puta-
tive risk genes for schizophrenia, selected on the basis 
of (1) GWAS findings for schizophrenia and (2) posi-
tional or functional candidates for this disorder, are 
associated with psychotic experiences
•	 Whether	 we	 could	 identify	 genetic	 variants	 for	 psy-
chotic experiences during adolescence using a GWA 
approach, and to what extent these show overlap with 
genetic findings for schizophrenia
Methods
Sample
This study examines data from 3483 children from the 
Avon Longitudinal Study of Parents and Children 
(ALSPAC) cohort who (1) participated in the Psychosis-
Like Symptoms interviews (PLIKSi) when they were aged 
12 (N = 6796) and 18 years (N = 4724) and (2) had genetic 
data available (analysis restricted to 1 child per nuclear 
family). The initial cohort consisted of 14 062 children 
born to residents of the former Avon Health Authority 
area who had an expected date of delivery between April 
1, 1991 and December 31, 1992 (www.alspac.bris.ac.uk). 
The cohort was set up to examine genetic and environ-
mental determinants of health and development (see 
Fraser et al15 and Boyd et al16 for further details). All sub-
jects and their parents gave written informed consent for 
this study. Ethical approval for the study was obtained 
from the ALSPAC Law and Ethics Committee and the 
Local Research Ethics Committees.
Measures
Psychotic Experiences. Psychotic experiences were 
assessed at ages 12 and 18  years using the semistruc-
tured PLIKSi,7,17 which draws on principles of standard-
ized clinical examination developed for the Schedule for 
Clinical Assessment in Psychiatry (SCAN). It includes 
11 “core” questions eliciting key psychotic experiences, 
covering hallucinations (visual and auditory), delusions 
(spied on, persecution, thoughts read, reference, control, 
grandiosity), and experiences of thought interference 
(broadcasting, insertion and withdrawal). Any unspeci-
fied delusions elicited were also rated. Cross-questioning 
was used to establish presence of symptoms, and coding 
followed glossary definitions and rating rules for SCAN.
Interviewers were psychology graduates trained in 
assessing the SCAN Psychosis Section and using the 
PLIKSi, and rated experiences as not present, suspected, 
or definitely psychotic. Unclear responses after probing 
were always “rated down,” and symptoms only rated as 
definite when a clear example was provided. The average 
κ values for interrater reliability at ages 12 and 18 were 
0.7217 and 0.83,7 respectively.
Our primary outcome was an interviewer rating of one 
or more definite psychotic experiences at either age 12 or 
age 18, compared to a rating of none at both time points. 
As a secondary analysis, we also examined associations 
with a broader outcome of any suspected or definite 
experiences compared with none at these time points.
Polygenic Score. We used the polygenic score analytic 
approach18 using the Schizophrenia Psychiatric Genome-
Wide Association Study Consortium (PGC-SCZ) data 
set19 as a discovery sample to identify alleles with which 
to generate polygenic scores in the test (ALSPAC) sub-
jects. Following the approach of the International 
Schizophrenia Consortium (ISC),11 sets of single nucleo-
tide polymorphisms (SNPs) were selected at a range of 
values (P < .5, P < .4, P < .3, P < .2, P < .1, P < .05, and 
P < .01) for evidence of association with schizophrenia in 
the PGC-SCZ sample and were used to derive scores in 
the ALSPAC sample (from 101 200 SNPs following link-
age disequilibrium [LD] pruning using a sliding window 
of 200 SNPs, at 5 SNP intervals, with an r2 cutoff  value 
of .2). The derived scores were based on the average num-
ber of risk alleles, each weighted by the effect size (lnOR) 
at each locus within the PGC-SCZ.
Single SNP Associations. SNPs were divided into 2 cat-
egories depending upon the strength of evidence for their 
association with schizophrenia.
Category 1 SNPs were selected for inclusion if  they 
were reported as showing genome-wide levels of sig-
nificance (P < 5 × 10−8) for association with schizophre-
nia, or a combined schizophrenia bipolar phenotype, 
and were not in strong LD (measured as r2) with other 
included SNPs (where r2 ≥.2, the most significant SNP 
from the PGC-SCZ was chosen). A search of studies in 
samples of European ancestry up to December 31, 2011 
identified 17 SNPs (13 within different genes and 4 in 
intergenic segments) that met these criteria. Ten SNPs 
were selected from the PGC-SCZ sample19 (MIR137 
rs1625579, ITIH3/4 rs2239547, TRIM26 rs2021722, 
CSMD1 rs10503253, CNNM2 rs7914558, NT5C2 
rs11191580, CACNA1C rs4765905 and intergenic SNPs 
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rs17662626 [343 kb from PCGEM1], rs7004633 [421 kb 
from MMP16], and rs12966547 [126 kb from CCDC68]). 
Two of these (ITIH3/4 rs2239547 and CACNA1C 
rs4765905) originally showed genome-wide significance 
for schizophrenia and bipolar samples combined but 
have shown genome-wide evidence for schizophrenia 
since.10 Six SNPs selected showed genome-wide evidence 
of association in meta-analyses of the ISC, S-GENE, 
and Molecular Genetics of Schizophrenia (MGS) sam-
ples (NOTCH4 rs3131296, PRSS16 rs6932590, NRGN 
rs12807809, TCF4 rs9960767),11,20,21 or extended meta-
analyses with other samples (rs2312147, 50 kb from 
VRK222 and ZNF804A rs134470623,24), and 1 SNP was 
selected from a consortium of Western European sam-
ples (AMBRA1 rs11819869).25
As an overall test of the hypothesis that these 17 SNPs 
that show the strongest evidence of association with 
schizophrenia are also associated with psychotic expe-
riences, we constructed a risk score whereby a score of 
1 was given for the presence of each risk allele at each 
independent SNP (r2 < .2), and then scores summed 
across SNPs to obtain an individual risk score. We then 
tested for association between the risk score (using both 
unweighted scores and scores weighted by effect sizes in 
the discovery samples) and our outcome measures.
Category 2 We examined a number of SNPs within 
genes (including PTBP2, NRXN1, FXR1, HLA-DQA1, 
MAD1L1, ANK3, NOS1, and RPGRIP1L) or intergenic 
regions that showed suggestive (P < 5 × 10−5), but not 
genome-wide, evidence of association in GWAS. We 
also examined SNPs within a number of genes (most 
identified through positional approaches) either hypoth-
esized to play a functional role on the pathogenesis of 
schizophrenia through affects on neurotransmitter 
metabolism (COMT, DAOA), receptor function (DRD2, 
GRM3, CHRNA3), myelination (OLIG2, MAGI2, 
PTPRZ1, QKI, CNP, NRG1, ERBB4), synaptic func-
tion (DTNBP1), or microtubule function (DISC1), or 
positional candidates (eg, TBX1 and GNB1L within the 
22q11 deletion syndrome).
Genome-Wide Association Studies. A total of 9912 
ALSPAC children were genotyped using the Illumina 
HumanHap550 quad genome-wide SNP genotyping 
platform by 23andMe subcontracting the Wellcome Trust 
Sanger Institute, Cambridge, UK and the Laboratory 
Corporation of America, Burlington, NC. Individuals 
were excluded from further analysis on the basis of having 
incorrect gender assignments, minimal or excessive het-
erozygosity (<0.320 and >0.345 for the Sanger data and 
<0.310 and >0.330 for the LabCorp data), disproportion-
ate levels of individual missingness (>3%), evidence of 
cryptic relatedness (>10% of alleles identical by descent), 
and being of non-European ancestry (as detected by a 
multidimensional scaling analysis seeded with HapMap 
2 individuals. EIGENSTRAT analysis revealed no addi-
tional obvious population stratification, and genome-wide 
analyses with other phenotypes indicate a low genomic 
inflation factor, with λ ≈ 1. The resulting data set con-
sisted of 8365 individuals and 500 527 SNPs. SNPs with a 
minor allele frequency of <1% and call rate of <95% were 
removed. Furthermore, only SNPs, which passed an exact 
test of Hardy–Weinberg equilibrium (P >5 × 10–7), were 
considered for further use. Genotypes were imputed with 
MACH 1.0.16 Markov Chain Haplotyping software,26,27 
using CEPH individuals from phase 2 of the HapMap 
project as a reference set (release 22).
Statistical Analysis
Logistic regression was used to test for association 
between each SNP and our psychosis outcomes under an 
additive genetic model. Results are presented as ORs and 
95% CIs per copy of test allele (see table 2) for individual 
SNPs, per schizophrenia risk allele increase for risk scores, 
and per SD for polygenic scores. Nonlinear associations 
between polygenic scores and outcomes were examined 
by inclusion of quadratic terms in the regression mod-
els. Adjusting for sex made no difference to any of the 
estimates reported. A  binomial test was used to exam-
ine whether SNPs showing evidence of association with 
psychotic experiences in the GWAS showed greater than 
chance evidence of association with schizophrenia in the 
PGC-SCZ sample. Analyses were conducted using Stata 
(version 11), PLINK (version 1.06),28,29 and mach2dat.26,27
Results
There were 4060 individuals who participated in the 
PLIKSi at ages 12 and 18  years, and 3483 (85.8%) of 
these had genetic data available that passed strict quality 
control criteria. Of these, 424 (12.2%) had definite psy-
chotic experiences at either age.
Schizophrenia Polygenic Score
There was no evidence that individuals who had higher 
polygenic scores (reflecting increased genetic risk for 
schizophrenia) were at an increased risk of  definite 
psychotic experiences during adolescence (table 1). 
Although, on average, individuals with definite psy-
chotic experiences had higher polygenic scores than 
those without, there was, at best, only very weak evi-
dence (without any correction for multiple testing) that 
this was different from random variation (strongest 
evidence at discovery sample P value cutoff  <.3; OR 
per SD increases in score = 1.08, 95% CI: 0.98, 1.20; 
P = .134). There was no evidence of  any nonlinear 
association with polygenic scores (P values for qua-
dratic terms ranged from .5 to .9; see online supple-
mentary table S1).
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Association With Schizophrenia Genome-Wide 
Significant SNPs
Three of the 17 schizophrenia genome-wide significant 
SNPs tested (table 2) showed some evidence of association 
with definite psychotic experiences (MIR137 rs1625579 
on chromosome 1, P = .012; intergenic SNP rs17662626 
near PCGEM1 on chromosome 2, P = .017; and NT5C2 
rs11191580 on chromosome 10, P = .036). However, for each 
of these SNPs, the risk allele for schizophrenia was reduced 
in frequency in those with definite psychotic experiences.
There was evidence of association between the risk 
score derived from the 17 schizophrenia genome-wide 
significant SNPs and definite psychotic experiences (OR 
per 1-point score increase = 0.96, 95% CI: 0.92, 0.99; P = 
.024), though again this indicated that psychotic experi-
ences were less likely in those with more schizophrenia 
risk alleles.
Association With Other Schizophrenia Candidate SNPs
Of 61 SNPs (47 SNPs at r2 <.2) examined (online supple-
mentary table S2), 6 showed some evidence of association 
with definite psychotic experiences (NRXN1 rs3850333, 
ERBB4 rs4673628, GRM3 rs6465084, MAGI2 rs6951046, 
GNB1L rs2269726, and COMT rs2097603), but none of 
Table 2. Association Between Schizophrenia Genome-Wide Significant SNPs and Definite Psychotic Experiences at Age 12 or 18
Ch. Gene SNP A1a A2a Frequency (A1) ORb L95% CI U95% CI P As SCZc
 1 MIR137 rs1625579 G T 0.18 1.25 1.05 1.49 .012 −
 1 VRK2 (IG) rs2312147 C T 0.62 0.99 0.85 1.15 .897 −
 2 ZNF804A rs1344706 A C 0.59 1.05 0.90 1.21 .536 +
 2 PCGEM1 (IG) rs17662626 A G 0.92 0.75 0.59 0.95 .017 −
 3 ITIH3/4 rs2239547 C T 0.27 1.05 0.89 1.24 .550 −
 6 PRSS16 rs6932590 C T 0.25 0.99 0.84 1.18 .935 +
 6 TRIM26 rs2021722 C T 0.77 1.10 0.93 1.31 .274 +
 6 NOTCH4 rs3131296 C T 0.85 0.96 0.79 1.18 .717 −
 8 CSMD1 rs10503253 A C 0.19 0.97 0.81 1.16 .729 −
 8 MMP16 (IG) rs7004633 A G 0.84 1.19 0.96 1.47 .107 −
10 CNNM2 rs7914558 A G 0.39 1.06 0.92 1.23 .425 −
10 NT5C2 rs11191580 C T 0.08 1.31 1.02 1.69 .036 −
11 NRGN rs12807809 C T 0.17 1.07 0.89 1.29 .478 −
11 AMBRA1 rs11819869 C T 0.82 0.89 0.74 1.07 .204 +
12 CACNA1C rs4765905 C G 0.34 0.97 0.83 1.13 .668 −
18 CCDC68 (IG) rs12966547 A G 0.40 1.13 0.97 1.31 .109 −
18 TCF4 rs9960767 A C 0.95 1.03 0.73 1.44 .881 −
Risk score (17 genome-wide hits) 0.96d 0.92 0.99 .024 −
Note: SNP, single nucleotide polymorphism; ch., chromosome; IG, intergenic; A1/A2, allele 1/allele 2, L95% CI, lower 95% CI; U95% CI, 
upper 95% CI; PGC-SCZ, Schizophrenia Psychiatric Genome-Wide Association Study Consortium.
aSchizophrenia risk alleles are italicized.
bPer allele 1.
cRisk allele for psychotic experiences same as for schizophrenia (SCZ) in PGC-SCZ sample (+), or different (−).
dPer risk allele (unweighted).
Table 1. Association Between Schizophrenia Polygenic Score (Per SDa) and Definite Psychotic Experiences at Age 12 or 18
P Value Cutoff in 
Discovery Sample OR LCI UCI P
Same Direction as 
Discovery Sample
.5 1.08 0.97 1.19 .158 +
.4 1.06 0.96 1.18 .247 +
.3 1.08 0.98 1.20 .134 +
.2 1.05 0.95 1.17 .311 +
.1 1.06 0.95 1.17 .296 +
.05 1.07 0.96 1.18 .230 +
.01 1.08 0.97 1.20 .148 +
Note: LCI, L95% CI; UCI, U95% CI.
aNo evidence of nonlinearity (including quadratic terms).
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these associations persisted after correction for multiple 
testing.
GWAS of Psychotic Experiences
Results of the GWAS are shown in figure 1. A quantile-
quantile (Q-Q) plot of the association test P values did 
not show deviation from what was expected under the 
assumption of no genetic association (figure 2), and the 
value of λ was 1.0. None of the 2 487 019 SNPs tested 
showed genome-wide evidence (P < 5 × 10−8) for associa-
tion with definite psychotic experiences. There were 121 
SNPs that showed moderate evidence of association (P < 
5 × 10−5), with 31 SNPs representing probable indepen-
dent signals (r2 < .2) (table 3; figure 1). There was no evi-
dence that these suggestive hits for psychotic experiences 
were enriched for genetic variants associated with schizo-
phrenia in the PGC-SCZ sample (binomial test, P > .99).
Secondary Analyses
Results for polygenic score and candidate SNPs were 
similar when we examined a broader outcome of sus-
pected or definite psychotic experiences (N = 912 [26.1%]) 
compared to none (2588 [73.9%]) (online supplementary 
tables S3–S5). No SNPs showed genome-wide evidence 
of association with this broader outcome, though 106 
SNPs showed suggestive evidence of association, with 36 
SNPs representing probable independent signals. There 
was no evidence that these suggestive hits were enriched 
for genetic variants associated with schizophrenia (bino-
mial test, P = .297).
Discussion
We utilized a number of  approaches to examine the 
extent to which genetic risk factors for schizophrenia 
are shared with those for psychotic experiences within 
the general population. We found no evidence that a 
schizophrenia polygenic score was associated with 
adolescent psychotic experiences, or that genetic vari-
ants, showing genome-wide evidence of  association 
with schizophrenia, were associated with psychotic 
experiences within the general population. In fact, we 
observed some evidence contrary to that hypothesized, 
with individuals who had a higher number of  risk 
alleles for genome-wide hits for schizophrenia show-
ing a decreased risk of  psychotic experiences in our 
sample.
Although a potential explanation for the lack of asso-
ciation between the schizophrenia polygenic score and 
psychotic experiences in our sample is low statistical 
power (eg, see Dudbridge30 for a discussion of power in 
relation to the variance in liability explained by polygenic 
score, given model assumptions), this seems an unlikely 
Fig. 1.  Manhattan plot for the genome-wide association studies of definite psychotic experiences at ages 12 or 18. The Y-axis shows 
–Log (P values) of the logistic regression analysis (additive genetic model) for single nucleotide polymorphisms tested with definite 
psychotic experiences at ages 12 or 18 compared to none at both time points.
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explanation for our findings. Further examination of 
data from the PGC-SCZ sample reveals that the odds 
of schizophrenia within individual studies are increased 
approximately 1.5-fold (lowest CI: approximately 1.3) for 
each SD increase in polygenic risk score derived exclud-
ing the target study. Based on this empirical data, our 
study has >99% power to detect an effect of this mag-
nitude. Furthermore, from our results, we can be highly 
confident of excluding an effect size greater than 1.2 per 
SD increase in score.
It would be surprising if  genetic factors associated with 
schizophrenia risk do not have any influence at all on inci-
dence of psychotic experiences in the general population. 
However, as our results demonstrate, if  polygenic risk for 
schizophrenia increases risk for psychotic experiences, 
its impact on the latter is very much weaker than for the 
clinical disorder. This is contrary to expectations if  the 
presence of psychotic experiences offers a strong indica-
tor of underlying genetic risk. General population stud-
ies with larger samples or which utilize more accurately 
defined polygenic risk for schizophrenia will be required 
to provide evidence of association for such weaker effects.
Even if  such evidence is forthcoming however, such a 
polygenic score is likely to be a weak tool for prediction 
of risk for psychotic experiences.30,31 For example, in the 
MGS and Cardiff  samples that were used to validate the 
polygenic score approach for schizophrenia, the polygenic 
score explained <5% of the variance for this disorder 
even though there was very strong statistical evidence of 
association between a polygenic score and schizophrenia 
in these samples.11 The relatively weak predictive power 
of the polygenic score for schizophrenia may have limited 
the ability to observe an association with psychotic expe-
riences in our study.
Samples of individuals with schizophrenia are likely to 
be enriched for genetic variants related to onset, severity, 
and chronicity of this disorder, while the effect of com-
mon schizophrenia risk alleles (the sort mainly accessed by 
polygenic score) may be on the development of cognitive 
abnormalities, negative symptoms, or thought disorder 
rather than on development of delusions or hallucina-
tions, which were the only aspects of the schizophrenia 
phenotype measured in this study. A recent case-control 
study of schizophrenia found no evidence of association 
between a polygenic score and positive or negative dimen-
sions of psychosis in controls, although this was a sample 
of only 148 individuals.32 It is also possible that the genetic 
contribution to the development of psychotic experiences 
changes over the life course, similar to depression and IQ33 
and is relatively small during adolescence.
The finding that 3 of the 17 SNPs, showing genome-wide 
evidence of association of schizophrenia, showed associa-
tion between the “protective” allele for schizophrenia and 
psychotic experiences in our data is counterintuitive and 
difficult to explain, but it adds further evidence against the 
hypothesis that the genetic etiology of psychotic experi-
ences is similar to that for schizophrenia. Although sam-
ple attrition in our study was not insubstantial, it is hard 
to envisage how selection bias could explain this finding. 
Attrition associated with psychotic experiences, family 
history of psychosis, or with genetic risk for psychosis 
could lead to estimates of association that are closer to 
the null, but patterns of attrition that would lead to an 
apparent protective effect of schizophrenia risk alleles on 
psychotic experiences are not easily envisaged.
We also examined the association between a genome-
wide array of variants and psychotic experiences. No 
variants showed genome-wide evidence of association, 
but although this is one of the largest population-based 
studies of psychotic experiences to date, we had very low 
statistical power to find such strength of evidence, given 
the magnitude of genetic effects described for most multi-
factorial complex outcomes, the number of events in our 
study, and the threshold required for genome-wide evi-
dence of association.
A number of SNPs showed suggestive evidence 
(P < 5 × 10−5) for association with psychotic experiences, 
but in the context of the number of markers examined, 
such findings are clearly likely to be chance observations. 
Although some of these SNPs are within genes for which 
some evidence of association with schizophrenia in the 
literature also exists,11,34 this is not surprising given the 
number of genes that have been associated with schizo-
phrenia, as well as the diversity of functional pathways 
in the brain that are hypothesized to be disrupted in this 
disorder. The most important finding from this GWAS, 
however, is not the strength of evidence of specific genes 
but the absence of evidence that the SNPs, showing 
Fig. 2.  Q-Q plot for the genome-wide association studies of 
definite psychotic experiences at ages 12 or 18.
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strongest evidence of association with psychotic experi-
ences in our study, were enriched for variants associated 
with schizophrenia in the PGC-SCZ sample.
If causal variants for such experiences could be identi-
fied, then studying the effects of these genes on neuroim-
aging, cognitive, and psychological phenotypes, as well as 
their impact on development of psychosis throughout the 
life course, in population-based longitudinal studies, such 
as the one used for this current study, could be a valuable 
asset in understanding pathological mechanisms underly-
ing disorders such as schizophrenia. However, that even the 
present sample is underpowered to detect such alleles points 
to the enormous challenges faced by population studies.
The thesis that studies of psychotic experiences in the 
general population may allow us to increase our under-
standing of the etiology of psychotic disorders relies upon 
the premise that the presence of such phenomena are an 
early expression of a pathology that, at its more extreme 
end, results in schizophrenia. However, the genetic overlap 
between psychotic experiences in the general population 
and schizophrenia is likely to be too limited to support the 
use of such experiences as an intermediate phenotype for 
schizophrenia.
Although the importance of psychotic experiences in 
general population samples and their relevance to disor-
ders such as schizophrenia remains to be determined,14,35 
the presence of such experiences may still impair function-
ing and cause substantial disability,7,36 and understanding 
their etiology could, therefore, be important in its own 
right. However, the assumption that it will be easier to 
understand the underlying mechanisms for such extended 
phenotypes or endophenotypes than for rarer and more 
severe disorder, such as schizophrenia, is unlikely to hold 
true.37 The potential advantages of being able to study a 
phenotype in a population-based sample, where problems 
of selection bias are likely to be minimized and where 
genetic effects on the development of psychosis over the 
life course can be examined, have to be weighed against 
the disadvantage of studying a phenotype that potentially 
has a more heterogeneous etiology than schizophrenia.
Table 3. Genome-Wide Association Studya of Psychotic Experiences at Age 12 or 18 vs None
Ch. BP Gene SNP
ALSPAC PGC-SCZ
Allele Frequency 1 P OR SE P P
 1 4677487 AJAP1 rs16839502 A,T 0.9569 .7327 0.507 0.167 4.79E-05 .085
 1 102105577 OLFM3 rs17125624 C,G 0.8685 .9969 0.657 0.102 3.65E-05 .386
 1 105942799 Null rs4489613 G,T 0.8312 .9562 1.629 0.114 1.99E-05 .137
 1 173693700 TNR rs863516 A,G 0.0355 .4617 2.834 0.242 1.68E-05 .225
 1 198349578 NR5A2 rs2249172 A,G 0.4802 .8229 1.417 0.082 1.96E-05 .935
 1 200012862 NAV1 rs523218 G,T 0.9374 .9967 0.556 0.136 1.63E-05 .110
 2 2752976 Null rs11127336 C,T 0.9809 .6373 0.328 0.265 2.62E-05 .218
 2 143889170 ARHGAP15 rs2381435 A,T 0.1918 .9965 1.48 0.088 8.02E-06 .105
 2 180239734 ZNF385B rs17770666 C,T 0.1476 .9488 0.602 0.125 4.78E-05 .636
 2 202453883 PFTK2 rs2192879 A,G 0.9179 .9962 0.581 0.116 2.67E-06 .451
 2 227777254 COL4A3 rs6756117 A,G 0.6206 .9982 0.739 0.074 4.45E-05 .061
 3 16065924 Null rs987858 A,T 0.2843 .4475 0.579 0.131 3.09E-05 .043
 3 61605054 PTPRG rs12489977 C,T 0.6098 .9978 0.727 0.075 2.29E-05 1.000
 3 130025938 Null rs13082400 A,G 0.9751 .8266 0.398 0.206 7.72E-06 .848
 3 176258264 NAALADL2 rs13319550 A,G 0.9418 .9631 0.546 0.143 2.27E-05 .822
 4 140771849 Null rs1027472 C,T 0.4784 .9984 1.362 0.075 3.82E-05 .525
 4 160707756 Null rs9992703 G,T 0.5924 .9993 1.416 0.079 9.92E-06 .300
 5 78903305 Null rs6453460 A,T 0.1714 .9088 1.507 0.099 3.79E-05 .507
 6 119566383 MAN1A1 rs9489621 C,T 0.5864 .9981 1.376 0.078 4.16E-05 .232
 7 15192064 Null rs6962150 G,T 0.8287 .9957 0.647 0.092 2.06E-06 .710
 9 17521968 Null rs2593371 C,T 0.7013 .9451 0.718 0.081 4.85E-05 .677
 9 36304566 Null rs17385743 C,T 0.8188 .9975 0.693 0.088 2.86E-05 .585
 9 71588335 Null rs11521712 A,G 0.8995 .9982 0.632 0.111 3.36E-05 .381
 9 87043180 Null rs7040848 A,G 0.5564 .9969 0.734 0.075 3.37E-05 .937
 9 136727589 COL5A1 rs4841924 A,G 0.9536 .6804 0.48 0.179 4.32E-05 .690
12 126484085 Null rs1879390 A,C 0.1164 .966 1.551 0.108 4.64E-05 .837
14 102183305 RCOR1 rs714827 A,G 0.9154 .9958 2.16 0.182 2.32E-05 .943
16 59019380 Null rs11643723 A,G 0.0489 .9951 1.857 0.149 3.26E-05 .532
16 86171466 Null rs17781622 A,G 0.8951 .9319 0.578 0.112 1.03E-06 .903
18 17892308 Null rs8086768 A,T 0.0942 .9964 1.613 0.113 2.31E-05 .323
18 40546336 SETBP1 rs2852779 G,T 0.1542 .9994 1.471 0.095 4.71E-05 .187
Note: ALSPAC, Avon Longitudinal Study of Parents and Children; BP, base-pair position. Abbreviations are explained in the first 
footnote to table 2.
aAll independent (r2 < .2) SNPs with evidence of association at P <5 × 10−5.
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Our findings, and in particular the magnitude of the 
effect we observed for the polygenic score compared with 
that for schizophrenia, indicate that the genetic architec-
ture of psychotic experiences in the general population is 
not likely to be comparable to that underlying schizophre-
nia. The implication of this is that while samples may be 
easier to collect, genetic studies of psychotic experiences 
are unlikely to aid understanding of the genetic etiology 
of schizophrenia, or, at the very least, will be substan-
tially underpowered compared to equivalent-sized sam-
ples of individuals with this disorder. It is possible that 
similar evaluation of other phenotypes, such as deficits in 
specific neurocognitive domains or abnormalities in neu-
roimaging pathways, may prove to be more informative in 
addressing this aim.
Supplementary Material
Supplementary material is available at http://schizophrenia 
bulletin.oxfordjournals.org.
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